Literature DB >> 16050566

Update on the management of ovarian germ cell tumors.

Karen H Lu1, David M Gershenson.   

Abstract

Malignant germ cell tumors of the ovary are rare. In contrast to epithelial ovarian cancer, malignant germ cell tumors occur primarily in girls and young women. In addition, with the refinement of chemotherapeutic regimens in the last several decades, overall disease-free survival rates are >95%. Recent advances have focused on preservation of fertility in the management of patients with these tumors. In a girl or young woman who presents with a pelvic mass, a gynecologist must consider the diagnosis of an ovarian germ cell tumor in the initial workup. Elevated tumor markers may assist in determining the diagnosis preoperatively. Appropriate intraoperative decision making is crucial to adequately treat and stage the cancer without compromising future fertility. For patients with stage I dysgerminoma or stage I low grade immature teratoma, no additional chemotherapy is indicated. However, patients with stage I disease of other germ cell histologies, as well as advanced-stage disease of all germ cell histologies, require adjuvant treatment with bleomycin, etoposide and cisplatin.

Entities:  

Mesh:

Year:  2005        PMID: 16050566

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  9 in total

Review 1.  Current Strategy for the Treatment of Ovarian Germ Cell Tumors: Role of Extensive Surgery.

Authors:  Jin Li; Xiaohua Wu
Journal:  Curr Treat Options Oncol       Date:  2016-08

2.  Massive Gastrointestinal Bleeding from Choriocarcinoma of the Ovary.

Authors:  Shiyam Kumar; Zaid R Raouf; P A M Saparamadu; Ikram A Burney
Journal:  Oman Med J       Date:  2018-11

3.  Results of RS-99 protocol for childhood solid tumors.

Authors:  Jiao-Yang Cai; Jing-Yan Tang; Ci Pan; Min Xu; Hui-Liang Xue; Min Zhou; Lu Dong; Qi-Dong Ye; Hua Jiang; Shu-Hong Shen; Jing Chen
Journal:  World J Pediatr       Date:  2010-02-09       Impact factor: 2.764

Review 4.  Clinicopathological factors and prognosis analysis of 39 cases of non-gestational ovarian choriocarcinoma.

Authors:  Xiaodie Liu; Xue Zhang; Yingxin Pang; Yanhui Ma; Xiaolei Zhang; Peishu Liu
Journal:  Arch Gynecol Obstet       Date:  2020-03-17       Impact factor: 2.344

5.  Residual tumor after the salvage surgery is the major risk factors for primary treatment failure in malignant ovarian germ cell tumors: a retrospective study of single institution.

Authors:  Chung Won Lee; Min Jong Song; Sung Taek Park; Eun Young Ki; Sung Jong Lee; Keun Ho Lee; Ki Sung Ryu; Jong Sup Park; Soo Young Hur
Journal:  World J Surg Oncol       Date:  2011-10-11       Impact factor: 2.754

6.  Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers.

Authors:  Christina E Hoei-Hansen; Sigrid M Kraggerud; Vera M Abeler; Janne Kaern; Ewa Rajpert-De Meyts; Ragnhild A Lothe
Journal:  Mol Cancer       Date:  2007-02-02       Impact factor: 27.401

Review 7.  Laparoscopic treatment of a Yolk Sac Tumor: case report and literature review.

Authors:  Maurizio Guida; Sandro Pignata; Anna Rita Palumbo; Gianmarco Miele; Maria Luisa Marra; Federica Visconti; Fulvio Zullo
Journal:  Transl Med UniSa       Date:  2013-09-02

8.  Fertility sparing approach as the standard of care in young patients with immature teratomas.

Authors:  Christos Iavazzo; George Vorgias; Paraskevi Evangelia Iavazzo; Ioannis D Gkegkes
Journal:  J Turk Ger Gynecol Assoc       Date:  2017-03-15

9.  Cisplatin induces differentiation in teratomas derived from pluripotent stem cells.

Authors:  Atsushi Kurata; Masakatsu Takanashi; Shin-Ichiro Ohno; Koji Fujita; Masahiko Kuroda
Journal:  Regen Ther       Date:  2021-06-08       Impact factor: 3.419

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.